Multidisciplinary care for cardiovascular risk in prostate cancer patients on hormone therapy
To Investigate the Effect of Multidisciplinary Care Approach on Cardiovascular Risk Modification in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
This study is testing if a team-based approach to care can help men with prostate cancer on hormone therapy lower their heart health risks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Male |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06163924 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the impact of a multidisciplinary care approach on cardiovascular risk modification in patients with prostate cancer who are receiving androgen deprivation therapy (ADT). It seeks to gather data on cardiovascular risk factors, monitoring, and treatment strategies to better understand how to mitigate the adverse cardiovascular effects associated with ADT. The study will involve adult men diagnosed with prostate cancer who are planning to undergo ADT for at least one year, focusing on their cardiovascular health throughout the treatment period.
Who should consider this trial
Good fit: Ideal candidates for this study are adult men aged 18-80 with histologically proven or clinically diagnosed prostate cancer who are planning to receive ADT for at least one year.
Not a fit: Patients with established major atherosclerotic cardiovascular disease or those who have received prior hormone therapy within the last year may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cardiovascular health and reduced morbidity for prostate cancer patients undergoing ADT.
How similar studies have performed: While there is limited data on the specific approach of this study, similar studies have indicated the importance of cardiovascular monitoring in patients undergoing ADT, suggesting potential for positive outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult men 18-80 years old * With histological proven prostate cancer or clinically diagnosed to have prostate cancer, * Planned for ADT for at least 1 year Exclusion Criteria: * Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation * Prior neoadjuvant or adjuvant hormone therapy within 1 year before * Refuse or unable to give written informed consent * Participation in an investigational program with interventions outside of routine clinical practice
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Chi Fai NG, Professor
- Email: ngcf@surgery.cuhk.edu.hk
- Phone: 852-3505-3933
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.